HC Wainwright Brokers Increase Earnings Estimates for MNPR

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities research analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a report issued on Monday, November 11th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings of ($1.68) per share for the year, up from their previous estimate of ($2.06). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($1.48) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.09.

Separately, Rodman & Renshaw started coverage on Monopar Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $50.00 target price on the stock.

Monopar Therapeutics Price Performance

MNPR stock opened at $18.09 on Thursday. The company has a 50-day moving average of $8.79 and a two-hundred day moving average of $5.19. The stock has a market capitalization of $95.52 million, a price-to-earnings ratio of -9.25 and a beta of 1.09. Monopar Therapeutics has a 52-week low of $1.37 and a 52-week high of $38.50.

Insider Transactions at Monopar Therapeutics

In other news, CFO Karthik Radhakrishnan bought 1,550 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was acquired at an average cost of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the purchase, the chief financial officer now owns 1,550 shares of the company’s stock, valued at $25,187.50. This trade represents a ? increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.